Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01912651 · ClinicalTrials.gov registry record · Phase 4
The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery
A Phase 4 study of Facial Defect, sponsored by University of Michigan.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT01912651: Recruiting Phase 4 study of Facial Defect, sponsored by University of Michigan.
NCT01912651 is a Phase 4 study of Facial Defect that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 300 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01912651, a Phase 4 study of Facial Defect, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Antibiotics are sometimes prescribed to patients who have had reconstructive surgery of wounds on their face using skin grafts. But, it is not yet known whether antibiotics improve the healing of skin grafts and reduce the risk of infections after surgery in these patients. It is known that antibiotics, like all medications, have side-effects although these are rare. This research study is designed to show us whether antibiotics improve wound healing or not, so that we may determine if we should continue using antibiotics even if they have side-effects in some patients. Our hypothesis is that patients treated with post-operative, systemic antibiotics will demonstrate a statistically significant improvement in the survival of their facial full thickness skin grafts compared to patients who are not treated with systemic antibiotics.
Primary Outcome
The primary outcomes will be graft failure rate where failure is defined as any tissue loss extending beyond the epithelium.
Conditions Studied
Interventions
- DRUG cephalexin
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2013-07 |
| Est. Completion | 2028-09 |
| Phase | Phase 4 |
What NCT01912651 shows while recruiting
NCT01912651 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Facial Defect appearing as the primary indexed condition, and to 1 intervention - of which cephalexin is the first listed.
NCT01912651 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT01912651 about?
NCT01912651 is a clinical study titled "The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery". Antibiotics are sometimes prescribed to patients who have had reconstructive surgery of wounds on their face using skin grafts. But, it is not yet known whether antibiotics improve the healing of skin grafts and reduce the risk of infections after surgery in these patients. It is known that antibiot...
What is the current status of trial NCT01912651?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2013-07. Estimated completion is 2028-09.
What conditions does trial NCT01912651 study?
This clinical trial studies the following conditions: Facial Defect.
What interventions are being tested in trial NCT01912651?
The interventions under investigation include: cephalexin (DRUG).
Who is sponsoring clinical trial NCT01912651?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01912651 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Facial Defect
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01912651's enrollment target sits among peer trials
300 269th of 2000 higher than 1,710 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia